Latest filings (excl ownership)
25-NSE
Exchange delisting
21 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7 Feb 24
8-K
Bankruptcy or Receivership
5 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
31 Jan 24
DEFA14A
Additional proxy soliciting materials
23 Jan 24
8-K
Material Modifications to Rights of Security Holders
23 Jan 24
DEFA14A
Additional proxy soliciting materials
3 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
3 Jan 24
8-K
Regulation FD Disclosure
3 Jan 24
8-K
Termination of a Material Definitive Agreement
21 Dec 23
DEFA14A
Additional proxy soliciting materials
4 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
4 Dec 23
8-K
DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update
28 Nov 23
DEFA14A
Additional proxy soliciting materials
15 Nov 23
DEFA14A
Additional proxy soliciting materials
15 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
15 Nov 23
DEFA14A
Additional proxy soliciting materials
15 Nov 23
8-K
DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Entry into a Material Definitive Agreement
19 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
17 Oct 23
PX14A6G
Letter to shareholders
17 Oct 23
DEFC14A
Proxy in contested solicitation
12 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
10 Oct 23
PREC14A
Preliminary proxy with contested solicitation
2 Oct 23
8-K
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
8 Sep 23
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
1 Sep 23
8-K
Entry into a Material Definitive Agreement
29 Aug 23
8-K
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
21 Aug 23
10-Q
2023 Q2
Quarterly report
18 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
8-K
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
3 Aug 23
424B4
Prospectus supplement with pricing info
3 Aug 23
EFFECT
Notice of effectiveness
2 Aug 23
8-K
Completion of Acquisition or Disposition of Assets
31 Jul 23
8-K
Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert
28 Jul 23
S-1/A
IPO registration (amended)
28 Jul 23
CORRESP
Correspondence with SEC
28 Jul 23
CORRESP
Correspondence with SEC
28 Jul 23
CORRESP
Correspondence with SEC
28 Jul 23
Latest ownership filings
SC 13G/A
INTRACOASTAL CAPITAL, LLC
6 Feb 24
4
John W. Jr. Dorbin
2 Nov 23
3
John W. Jr. Dorbin
2 Nov 23
4
SETH COHEN
25 Oct 23
3
SETH COHEN
25 Oct 23
SC 13D/A
Versi Group LLC
26 Sep 23
4
Ebrahim Versi
19 Sep 23
SC 13G
INTRACOASTAL CAPITAL, LLC
10 Aug 23
SC 13D
Versi Group LLC
5 Jun 23
4
Ebrahim Versi
30 May 23
4
Meera J. Desai
30 May 23
4
Jannine Versi
30 May 23
3
Jannine Versi
30 May 23
3
Ebrahim Versi
30 May 23
4
HOWARD C BIRNDORF
16 Nov 22
4
DENNIS J PHD CARLO
27 May 22
3
VICKIE S REED
26 May 22
4
VICKIE S REED
26 May 22
4
Ronald B. Moss
22 Mar 22
4
David J. Marguglio
22 Mar 22
4
DENNIS J PHD CARLO
22 Mar 22
4
David C. Benedicto
22 Mar 22
5
David J. Marguglio
14 Feb 22
4
David C. Benedicto
3 Dec 21
4
Ronald B. Moss
3 Dec 21
4
David J. Marguglio
3 Dec 21
4
DENNIS J PHD CARLO
3 Dec 21
4
Meera J. Desai
6 Oct 21
3
Meera J. Desai
6 Oct 21
3
David C. Benedicto
2 Jun 21
4
Robert O Hopkins
23 Feb 21
4
David J. Marguglio
23 Feb 21
4
Ronald B. Moss
23 Feb 21
4
DENNIS J PHD CARLO
23 Feb 21
5
David J. Marguglio
16 Feb 21
5
Karen K. Daniels
16 Feb 21
5
Robert O Hopkins
16 Feb 21
5
Ronald B. Moss
16 Feb 21
5
DENNIS J PHD CARLO
16 Feb 21
SC 13G/A
CVI Investments, Inc.
16 Feb 21